Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder

Wu, Ping; Yu, Hui; Peng, Shichun; Dauvilliers, Yves; Wang, Jian; Ge, Jingjie; Zhang, Huiwei; Eidelberg, David; Ma, Yilong; Zuo, Chuantao

doi:10.1093/brain/awu290

Cited by 137 publications

(149 citation statements)

References 33 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…In line with 2 previous studies, RBD subjects significantly expressed the PDRP 12, 13. Although on average, PDRP z ‐scores were lower in RBD subjects compared with PD/DLB, more than half of the RBD subjects already had a PDRP z ‐score in the range of PD patients.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

et al. 2017

View full text Add to dashboard Cite

BackgroundIdiopathic REM sleep behavior disorder is a prodromal stage of Parkinson's disease and dementia with Lewy bodies. Hyposmia, reduced dopamine transporter binding, and expression of the brain metabolic PD‐related pattern were each associated with increased risk of conversion to PD. The objective of this study was to study the relationship between the PD‐related pattern, dopamine transporter binding, and olfaction in idiopathic REM sleep behavior disorder.MethodsIn this cross‐sectional study, 21 idiopathic REM sleep behavior disorder subjects underwent 18F‐fluorodeoxyglucose PET, dopamine transporter imaging, and olfactory testing. For reference, we included 18F‐fluorodeoxyglucose PET data of 19 controls, 20 PD patients, and 22 patients with dementia with Lewy bodies. PD‐related pattern expression z‐scores were computed from all PET scans.ResultsPD‐related pattern expression was higher in idiopathic REM sleep behavior disorder subjects compared with controls (P = 0.048), but lower compared with PD (P = 0.001) and dementia with Lewy bodies (P < 0.0001). PD‐related pattern expression was higher in idiopathic REM sleep behavior disorder subjects with hyposmia and in subjects with an abnormal dopamine transporter scan (P < 0.05, uncorrected).ConclusionPD‐related pattern expression, dopamine transporter binding, and olfaction may provide complementary information for predicting phenoconversion. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

show abstract

Section: Discussionsupporting

confidence: 90%

“…To date, 2 groups have reported that RBD subjects have higher PDRP subject scores compared with controls 12, 13. In a longitudinal study of 17 RBD subjects, baseline PDRP expression was associated with a high risk of developing PD or DLB within 5 years 12…”

mentioning

confidence: 99%

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Two studies demonstrated that idiopathic RBD patients significantly express the PDRP (44,45). This finding was recently confirmed by our group (Meles et al, unpublished data, 2013(Meles et al, unpublished data, -2016.…”

Section: Predicting Pd Onset In Idiopathic Rbdsupporting

confidence: 73%

Metabolic Imaging in Parkinson Disease

et al. 2016

View full text Add to dashboard Cite

This review focuses on recent human 18 F-FDG PET studies in Parkinson disease. First, an overview is given of the current analytic approaches to metabolic brain imaging data. Next, we discuss how 18 F-FDG PET studies have advanced understanding of the relation between distinct brain regions and associated symptoms in Parkinson disease, including cognitive decline. In addition, the value of 18 F-FDG PET studies in differential diagnosis, identifying prodromal patients, and the evaluation of treatment effects are reviewed. Finally, anticipated developments in the field are addressed.

show abstract

“…Green and red lines represent summary receiver-operating-characteristic curves of observer-dependent visual reads supported by, respectively, voxel-based statistical analyses (methods 1.1 and 1.2 in Table 1 hemisphere of patients with hemiparkinsonism (65). Likewise, recent studies demonstrated that expression of the PD-related pattern is also increased in the rapid-eye-movement sleep behavior disorder (66,67), being a significant predictor of phenoconversion to PD or DLB (assessed with perfusion SPECT (66)). In parallel to the respective metabolic changes (i.e., decrease in putamen/pallidum, sensorimotor cortex, and cerebellum; increase in precuneus) and symptom improvement, expression of the PD-related pattern was also found to decline with levodopa administration and deep-brain stimulation of the subthalamic nucleus in PD (68).…”

Section: Disease-specific Patterns Of Regional Glucose Metabolismmentioning

confidence: 97%

¹⁸F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment

et al. 2017

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) describe the clinical demand and rationale for differential diagnosis in parkinsonism, (2) recognize and differentiate the disease-specific patterns of regional glucose metabolism associated with Parkinson disease and the different atypical parkinsonian syndromes, and (3) identify regional metabolic changes that predict cognitive decline in Parkinson disease.Financial Disclosure: Dr. Meyer receives support from GE and Piramal for a research study outside the present topic. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA category 1 credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through December 2020.Accurate differential diagnosis of parkinsonism is of paramount therapeutic and prognostic importance. In addition, with the development of invasive therapies and novel disease-specific therapies, strategies for patient enrichment in trial populations are of growing importance. Imaging disease-specific patterns of regional glucose metabolism with PET and 18 F-FDG allows for a highly accurate distinction between Parkinson disease (PD) and atypical parkinsonian syndromes, including multiple-system atrophy, progressive supranuclear palsy, and corticobasal degeneration. On the basis of a preliminary metaanalysis of currently available studies with inclusion of multiple disease groups, we estimated that the diagnostic sensitivity and specificity for visual PET readings supported by voxel-based statistical analyses for diagnosis of atypical parkinsonian syndromes are 91.4% and 90.6%, respectively. The diagnostic specificity of 18 F-FDG PET for diagnosing multiple-system atrophy, progressive supranuclear palsy, and corticobasal degeneration was consistently shown to be high (.90%), whereas sensitivity was more variable (.75%). It is increasingly acknowledged that cognitive impairment represents a major challenge in PD, with mild cognitive impairment being a prodromal stage of PD with dementia (PDD). In line with clinical and neuropsychologic studies, recent PET studies demonstrated that posterior cortical dysfunction in nondemented PD patients precedes cognitive decline and the development of PDD by several years. Taken together, the current literature underscores the utility of 18 F-FDG PET for diagnostic evaluation of parkinsonism and the promising role of 18 F-FDG PET for assessment and risk stratification of cognitive impairment in PD.

show abstract

Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder

Cited by 137 publications

References 33 publications

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

Metabolic Imaging in Parkinson Disease

¹⁸F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment

Contact Info

Product

Resources

About

Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder

Cited by 137 publications

References 33 publications

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

Metabolic Imaging in Parkinson Disease

18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment

Contact Info

Product

Resources

About

¹⁸F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment